AI Article Synopsis
- - The study examines how MRI-visible perivascular spaces (PVS) relate to the effectiveness of levodopa treatment in patients with Parkinson's disease (PD), aiming to improve personalized treatment approaches.
- - Analyzed data from 327 PD patients who underwent MRI and levodopa response testing revealed no significant differences in PVS characteristics between those who responded well to the medication and those who did not.
- - The findings conclude that MRI-visible PVS do not serve as reliable indicators for predicting how well patients with PD will respond to levodopa treatment.
Article Abstract
Purpose: Inter-individual difference in levodopa responsiveness is a challenge for physicians to administer personalized treatment for patients with Parkinson's disease (PD). Previous studies demonstrated that magnetic resonance imaging (MRI)-visible perivascular spaces (PVS) might lead to an incomplete response to levodopa. This study aimed to investigate the association between MRI-visible PVS and levodopa responsiveness in patients with PD.
Methods: This cross-sectional study enrolled a total of 327 patients with PD (median age 64.0[57.0-68.0] years, 180 male) who had undergone high-resolution T2-weighted structural MRI at our hospital between 2019 and 2023. An acute levodopa challenge test was performed to evaluate levodopa responsiveness. The patients were divided into two groups: levodopa responsive (MDS-UPDRS-III reduction ≥ 33 %, n = 274) and irresponsive groups (MDS-UPDRS-III reduction < 33 %, n = 53). We employed quantitative and semi-quantitative methods to evaluate MRI-visible PVS in patients with PD, including PVS number, volume fraction, and visual score. Additionally, the imaging features of the levodopa-responsive and irresponsive groups were compared.
Results: There were no significant differences in PVS number, volume fraction, and visual score between the levodopa-responsive and -irresponsive groups. The indicators from quantitative and semi-quantitative analyses of PVS were not found to be independent predictors of levodopa responsiveness. None of the indicators from the quantitative or semi-quantitative analyses of PVS were significantly associated with poor responsiveness to levodopa treatment.
Conclusions: MRI-visible PVS are not independently associated with levodopa responsiveness, and their value in predicting levodopa responsiveness in patients with PD is limited.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejrad.2024.111844 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Use of the MNCD Classification to Monitor Clinical Stage and Response to Levodopa-Entacapone-Carbidopa Intestinal Gel Infusion in Advanced Parkinson's Disease.
Brain Sci
December 2024
Hospital Infanta Sofía, San Sebastián de los Reyes, 28702 Madrid, Spain.
Background And Objective: Staging Parkinson's disease (PD) with a novel simple classification called MNCD, based on four axes (Motor; Non-motor; Cognition; Dependency) and five stages, correlated with disease severity, patients' quality of life and caregivers' strain and burden. Our aim was to apply the MNCD classification in advanced PD patients treated with device-aided therapy (DAT).
Patients And Methods: A multicenter observational retrospective study of the first patients to start the levodopa-entacapone-carbidopa intestinal gel (LECIG) in Spain was performed (LECIPARK study).
The degeneration of midbrain dopamine (DA) neurons disrupts the neural control of natural behavior, such as walking, posture, and gait in Parkinson's disease. While some aspects of motor symptoms can be managed by dopamine replacement therapies, others respond poorly. Recent advancements in machine learning-based technologies offer opportunities for unbiased segmentation and quantification of natural behavior in both healthy and diseased states.
View Article and Find Full Text PDFAttenuated afferent inhibition correlated with impaired gait performance in Parkinson's disease patients with freezing of gait.
Front Aging Neurosci
December 2024
Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Background: The neural mechanisms underlying freezing of gait (FOG) in Parkinson's disease (PD) have not been completely comprehended. Sensory-motor integration dysfunction was proposed as one of the contributing factors. Here, we investigated short-latency afferent inhibition (SAI) and long-latency afferent inhibition (LAI), and analyzed their association with gait performance in FOG PD patients, to further validate the role of sensorimotor integration in the occurrence of FOG in PD.
View Article and Find Full Text PDFEthylenediamine assist preparation of carbon dots with novel biomass for highly sensitive detection of levodopa.
RSC Adv
January 2025
Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences, Collaborative Innovation Center of One Health, Hainan University Haikou 570228 China
Levodopa (l-Dopa), a precursor drug for dopamine has been widely used to treat Parkinson's disease. However, excess accumulation of l-Dopa in the body may cause movement disorders and uncontrollable emotions. Therefore, it is vital to monitor l-Dopa levels in patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!